EIR Biopharma, a preclinical biotech developing in-licensed therapies for eye diseases, filed on Tuesday with the SEC to raise up to $17 million in an initial public offering.
The San Francisco, CA-based company plans to raise $17 million by offering 3.8 million shares at a price range of $4 to $5.
EIR Biopharma is an early-stage biopharmaceutical developer focused on treatments for eye diseases. It licenses preclinical drug candidates from academic institutions and advances them toward clinical development, targeting assets that address defined unmet needs. Its product candidates include EIR-0205, a small-molecule therapy in development for dry age-related macular degeneration (dry AMD) designed to extract lipofuscin from the retinal epithelium, and EIR-1003, a peptidomimetic candidate designed to mimic ephrin ligands and promote retinal nerve regeneration in optic nerve injury. The company is conducting IND-enabling activities for both programs and plans to initiate human clinical studies beginning in 2027.
EIR Biopharma was founded in 2022 and plans to list on the NYSE American, although it has not yet selected a symbol (RC: ticker: EIRB.RC). Kingswood Capital Markets is the sole bookrunner on the deal.
